Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Orphan Drugs Market by Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, and Other Rare Diseases), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

LI_17204
Pages: 195
Apr 2017 | 11728 Views
face gplus_n
Author's : Onkar Sumant & Sohail Shaikh
Tables: 67
Charts: 65
twit_n pr_n

Orphan Drugs Market Overview:

Global Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan drug can be defined as a pharmaceutical agent specifically designed to treat rare (orphaned) diseases. These diseases differ from usual diseases as their prevalence rate is very low and hence appeal to a very small patient population. Therefore, as compared to non-orphan drugs, these drugs do not guarantee feasible returns on investment. However, various government authorities encourage to develop and market such drugs. Cost associated with the development of these drugs is higher when compared with non-orphan drugs. The different indications for which orphan drugs are used include lymphoma, leukemia, cystic fibrosis, and others.

The demand for the orphan drugs has increased significantly owing to surge in prevalence of rare diseases. In addition, the rise in awareness among the populace regarding rare diseases, increase in R&D investment, and drug development drive the market growth.

The orphan drugs market is segmented based on disease type, indication, and geography. Based on disease type, the industry is divided into oncologic diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases. In the disease type segment, oncologic diseases occupied dominant share in 2015. In addition, it is expected to maintain the trend during the forecast period. This is due to the array of different forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population.

Drivers, Restraints, and opportunities

The impact of the driving factors is expected to overcome the effect of restraints. Moreover, growth in novel indications for known orphan drugs and untapped emerging economies are expected to provide new market opportunities to orphan drug manufacturers in the near future.

Global Orphan Drugs Market: Key Product Segment

North America accounted for the largest market share in the orphan drugs market in 2015, and is expected to retain its dominance throughout the forecast period.

The key players operating in the global orphan drug market include AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Pfizer Inc. and Sanofi.

Other prominent players in the value chain include Bayer HealthCare Pharmaceuticals Inc., Vertex Pharmaceuticals, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Amgen Inc., Biogen Idec, Actelion Pharmaceuticals Ltd, AstraZeneca plc, and Janssen Biotech, Inc.

Orphan Drugs Market Report Key Benefits:

  • It provides an in-depth analysis with current trends and future estimations to elucidate the imminent investment pockets
  • It offers a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities
  • It includes profiles of key market players and their strategies, which helps in understanding competitive outlook of the market
  • It consists of Porters Five Forces model to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players

Orphan Drugs Market Key Segments:

By Disease Type

  • Oncologic Diseases
  • Metabolic Diseases
  • Hematologic and Immunologic Diseases
  • Infectious Diseases
  • Neurologic Diseases
  • Other Rare Diseases

By Indication

  • Non-Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Cystic Fibrosis
  • Glioma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Duchenne Muscular Dystrophy
  • Graft vs Host Disease
  • Renal Cell Carcinoma
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS.

3.4.1. Patent analysis by year (2010-2016)
3.4.2. Patent analysis by region
3.4.3. Patent analysis by indication

3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Favorable government policies
3.6.1.2. Availability of exclusivity for orphan drugs
3.6.1.3. Surge in prevalence of rare diseases

3.6.2. Restraints

3.6.2.1. Limited patient pool for clinical trials and product marketing
3.6.2.2. High treatment costs per patient

3.6.3. Opportunities

3.6.3.1. Use of orphan drugs for novel conditions/indications
3.6.3.2. Untapped emerging markets

Chapter: 4 ORPHAN DRUGS MARKET, BY DISEASE TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLOGICAL DISEASES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. METABOLIC DISEASES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. HEMATOLOGIC AND IMMUNOLOGIC DISEASES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. INFECTIOUS DISEASES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. NEUROLOGIC DISEASES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHER RARE DISEASES

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

Chapter: 5 ORPHAN DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market Size and Forecast

5.2. NON-HODGKIN’S LYMPHOMA

5.2.1. Market size and forecast

5.3. ACUTE MYELOID LEUKEMIA

5.3.1. Market size and forecast

5.4. CYSTIC FIBROSIS

5.4.1. Market size and forecast

5.5. GLIOMA

5.5.1. Market size and forecast

5.6. PANCREATIC CANCER

5.6.1. Market size and forecast

5.7. OVARIAN CANCER

5.7.1. Market size and forecast

5.8. MULTIPLE MYELOMA

5.8.1. Market size and forecast

5.9. DUCHENNE MUSCULAR DYSTROPHY

5.9.1. Market size and forecast

5.10. GRAFT VS. HOST DISEASE

5.10.1. Market size and forecast

5.11. RENAL CELL CARCINOMA

5.11.1. Market size and forecast

5.12. OTHERS

5.12.1. Market size and forecast

Chapter: 6 ORPHAN DRUGS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. UK market size and forecast
6.3.3.3. France market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Australia market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

Chapter: 7 COMPANY PROFILES

7.1. ABBVIE INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AEGERION PHARMACEUTICALS, INC. (NOVELION THERAPEUTICS INC.)

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BRISTOL-MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segment
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. CELGENE CORPORATION

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. HOFFMANN-LA ROCHE AG

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. GLAXOSMITHKLINE PLC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. JOHNSON & JOHNSON

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVARTIS AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. PFIZER INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. SANOFI

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

 LIST OF TABLES

TABLE 1. ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 2. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF ONCOLOGICAL DISEASES
TABLE 3. ONCOLOGICAL DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF METABOLIC DISEASES
TABLE 5. METABOLIC DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF HEMATOLOGIC AND IMMUNOLOGIC DISEASES
TABLE 7. HEMATOLOGIC AND IMMUNOLOGIC DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF INFECTIOUS DISEASES
TABLE 9. INFECTIOUS DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. KEY ORPHAN THERAPEUTIC DRUGS FOR RARE FORMS OF NEUROLOGIC DISEASES
TABLE 11. NEUROLOGIC DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. OTHER RARE DISEASES ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13. ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 14. NON-HODGKIN'S LYMPHOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. ACUTE MYELOID LEUKEMIA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16. CYSTIC FIBROSIS ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17. GLIOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18. PANCREATIC CANCER ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19. OVARIAN CANCER ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20. MULTIPLE MYELOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21. DUCHENNE MUSCULAR DYSTROPHY ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22. GRAFT VS. HOST DISEASE ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23. RENAL CELL CARCINOMA ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24. OTHER INDICATIONS ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25. ORPHAN DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26. NORTH AMERICA ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 27. NORTH AMERICA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 28. NORTH AMERICA ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 29. EUROPE ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 30. EUROPE ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 31. EUROPE ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 32. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 33. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 34. ASIA-PACIFIC ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 35. LAMEA ORPHAN DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 36. LAMEA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2014-2022 ($MILLION)
TABLE 37. LAMEA ORPHAN DRUGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 38. ABBVIE: COMPANY SNAPSHOT
TABLE 39. ABBVIE: OPERATING SEGMENTS
TABLE 40. ABBVIE: OPERATING SEGMENTS
TABLE 41. AEGERION PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 42. AEGERION PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 43. AEGERION PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 44. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 45. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 46. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 47. CELGENE: COMPANY SNAPSHOT
TABLE 48. CELGENE: OPERATING SEGMENTS
TABLE 49. CELGENE: PRODUCT PORTFOLIO
TABLE 50. ROCHE: COMPANY SNAPSHOT
TABLE 51. ROCHE: OPERATING SEGMENT
TABLE 52. ROCHE: PRODUCT PORTFOLIO
TABLE 53. GSK: COMPANY SNAPSHOT
TABLE 54. GSK: OPERATING SEGMENTS
TABLE 55. GSK: PRODUCT PORTFOLIO
TABLE 56. J&J: COMPANY SNAPSHOT
TABLE 57. J&J: OPERATING SEGMENTS
TABLE 58. J&J: PRODUCT PORTFOLIO
TABLE 59. NOVARTIS: COMPANY SNAPSHOT
TABLE 60. NOVARTIS: OPERATING SEGMENTS
TABLE 61. NOVARTIS: PRODUCT PORTFOLIO
TABLE 62. PFIZER: COMPANY SNAPSHOT
TABLE 63. PFIZER: OPERATING SEGMENTS
TABLE 64. PFIZER: PRODUCT CATEGORY
TABLE 65. SANOFI: COMPANY SNAPSHOT
TABLE 66. SANOFI: OPERATING SEGMENTS
TABLE 67. SANOFI: PRODUCT PORTFOLIO

 LIST OF FIGURES

FIGURE 1. ORPHAN DRUGS MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN ORPHAN DRUGS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE AND DISTRIBUTION
FIGURE 4. TOP WINNING STRATEGIES: TYPE AND COMPANY
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. PATENT REGISTERED/APPROVED- BY YEAR
FIGURE 12. PATENT REGISTERED/APPROVED- BY REGION
FIGURE 13. PATENT REGISTERED/APPROVED- BY INDICATION
FIGURE 14. COSTS PER YEAR ASSOCIATED WITH MOST EXPENSIVE ORPHAN DRUGS
FIGURE 15. ORPHAN DRUGS MARKET: DISEASE TYPE SEGMENTATION
FIGURE 16. CANCER: NUMBER OF DEATHS (UNIT) IN U.S., 2017 ESTIMATES
FIGURE 17. ORPHAN DRUGS MARKET: DISEASE INDICATION SEGMENTATION
FIGURE 18. U.S. ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 19. CANADA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 20. MEXICO ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 21. GERMANY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 22. UK ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 23. FRANCE ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 24. ITALY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 25. REST OF EUROPE ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 26. JAPAN ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 27. CHINA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 28. INDIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 29. AUSTRALIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 31. BRAZIL ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 32. TURKEY ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 33. SAUDI ARABIA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 34. SOUTH AFRICA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 35. REST OF LAMEA ORPHAN DRUGS MARKET, 2014-2022 ($MILLION)
FIGURE 36. ABBVIE: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. ABBVIE: REVENUE BY PRODUCT, 2016 (%)
FIGURE 38. ABBVIE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 39. AEGERION PHARMACEUTICALS: REVENUE, 2013-2015 ($MILLION)
FIGURE 40. AEGERION PHARMACEUTICALS: REVENUE BY PRODUCT, 2015 (%)
FIGURE 41. AEGERION PHARMACEUTICALS: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 42. BRISTOL-MYERS SQUIBB: REVENUE, 2014-2016 ($MILLION)
FIGURE 43. BRISTOL-MYERS SQUIBB: REVENUE BY PRODUCTS, 2016 (%)
FIGURE 44. BRISTOL-MYERS SQUIBB: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. CELGENE: REVENUE, 2014-2016 ($MILLION)
FIGURE 46. CELGENE: REVENUE BY PRODUCT, 2016 (%)
FIGURE 47. CELGENE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 48. ROCHE: REVENUE, 2014-2016 ($MILLION)
FIGURE 49. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 50. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 51. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 52. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 53. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 54. J&J: REVENUE, 2014-2016 ($MILLION)
FIGURE 55. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. NOVARTIS: REVENUE, 2014-2016 ($MILLION)
FIGURE 58. NOVARTIS: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 59. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 ($MILLION)
FIGURE 60. PFIZER: REVENUE, 2014-2016 ($MILLION)
FIGURE 61. PFIZER: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 62. PFIZER: REVENUE BY GEOGRAPHY, 2016 ($MILLION)
FIGURE 63. SANOFI: REVENUE, 2014-2016 ($MILLION)
FIGURE 64. SANOFI: REVENUE BY SEGMENT, 2016 ($MILLION)
FIGURE 65. SANOFI: REVENUE BY GEOGRAPHY, 2016 ($MILLION)

 

Orphan drugs have positively impacted diverse fields of therapeutics and treatment. Diseases that were otherwise debilitating and life-threatening can be managed through orphan drug administration. These drugs have also contributed significantly in diagnosis and prevention of oncologic, metabolic, immunologic, neurologic, and other rare diseases. Orphan drugs are expected to witness high adoption rate with increase in distinct indications and interventions, such as lymphomas, carcinomas, leukemia, and others. Orphan drug market has gained momentum in the healthcare industry and pharmaceutical sector owing to the favorable government policies, conducive regulations abiding orphan drugs, and market exclusivity for these drugs. In addition, surge in prevalence of rare diseases also drives the market growth.

There is an increase in demand for orphan drugs due to the rise in awareness among the populace regarding orphan drugs for rare disease treatment, especially in the developed regions of the world. However, high treatment costs per patient, limited patient pool for clinical trial, and product marketing restrict market growth. At present, oncologic diseases treatment through orphan drugs hold a maximum share in the global orphan drugs market and is expected to maintain this trend during the study period. This is attributed to the array of different forms of rare cancers, such as leukemia, angiosarcoma, myeloma, and others prevalent in the patient pool.

Increase in awareness regarding orphan drugs and investment in research, innovation, and drug development fuel the demand for novel orphan drugs, especially those that treat different forms of cancer. The employment of novel orphan drugs is highest in North America, owing to the increase in adoption of these drugs, followed by Europe and Asia-Pacific region.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Orphan Drugs Market- Global Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts